Double-blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Increased levels of cortisol during acute alcohol withdrawal have been linked to cognitive deficits and depression. Preclinical research found that the glucocorticoid Type II receptor antagonist, mifepristone, prevented some of the neurotoxic effects of withdrawal and memory loss. Clinical trials have shown mifepristone effective in the treatment of depression. This study aims to examine the extent to which the glucocorticoid Type II receptor antagonist, mifepristone, when given to alcohol dependent males during the acute phase of alcohol withdrawal, will protect against the subsequent memory loss and depressive symptoms during abstinence from alcohol. METHODS/DESIGN: The study is a Phase 4 therapeutic use, "Proof of Concept" trial. The trial is a double-blind randomised controlled clinical trial of mifepristone versus inactive placebo. The trial aims to recruit 120 participants referred for an inpatient alcohol detoxification from community alcohol teams, who meet the inclusion criteria; 1) Male, 2) Aged 18-60 inclusive, 3) alcohol dependent for 5 or more years. A screening appointment will take place prior to admission to inpatient alcohol treatment units to ensure that the individual is suitable for inclusion in the trial in accordance with the inclusion and exclusion criteria. On admission participants are randomised to receive 600 mg a day of mifepristone (200 mg morning, afternoon and evening) for 7 days and 400 mg for the subsequent 7 days (200 mg morning and evening) or the equivalent number of placebo tablets for 14 days. Participants will remain in the trial for 4 weeks (at least 2 weeks as an inpatient) and will be followed up at 3, 6 and 12 months post randomisation. Primary outcome measures are cognitive function at week 3 and 4 after cessation of drinking and symptoms of depression over the 4 weeks after cession of drinking, measured using the Cambridge Neuropsychological Test Automated battery and Beck Depression Inventory, respectively. Secondary outcome measures are severity of the acute phase of alcohol withdrawal, alcohol craving, symptoms of protracted withdrawal and maintenance of abstinence and levels of relapse drinking at follow-up. DISCUSSION: The current trial will provide evidence concerning the role of glucocorticoid Type II receptor activation in cognitive function and depression during acute alcohol withdrawal and the efficacy of treatment with mifepristone. ISRCTN: ISRCTN54001953, Registered 29th September 2011.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988 · cited 1×
“Severity of the overall syndrome of acute alcohol withdrawal will be monitored using the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) [54].”
MethodA scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale
Snaith, R. P., Hamilton, M., Morley, S., Humayan, A., Hargreaves, D., & Trigwell, P. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.1.99 · Cited by 1,778
Stress, Glucocorticoids, and Damage to the Nervous System: The Current State of Confusion
Sapolsky, R. M. (1996) · Stress · doi:10.3109/10253899609001092 · Cited by 738
Neurocognitive impairment associated with alcohol use disorders: Implications for treatment.
Bates, M. E., Bowden, S. C., & Barry, D. (2002) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.10.3.193 · Cited by 406
Benzodiazepines, memory and mood: a review
Valerie Curran, H. (1991) · Psychopharmacology · doi:10.1007/bf02316856 · Cited by 401 · cited 1×
“Urine samples taken on the day of CANTAB testing will be screened for the presence of residual chlordiazepoxide or its active metabolites, which may affect cognitive performance [53].”
BackgroundAn open label trial of C-1073 (mifepristone) for psychotic major depression*
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01432-4 · Cited by 320
Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats
Vendruscolo, L. F., Barbier, E., Schlosburg, J. E., Misra, K. K., Whitfield, T. W., Logrip, M. L., Rivier, C., Repunte-Canonigo, V., Zorrilla, E. P., Sanna, P. P., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0069-12.2012 · Cited by 319
Cognitive disturbance in outpatient depressed younger adults: evidence of modest impairment
Grant, M. M., Thase, M. E., & Sweeney, J. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01072-6 · Cited by 319
Young, A. H., Gallagher, P., Watson, S., Del-Estal, D., Owen, B. M., & Nicol Ferrier, I. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300471 · Cited by 318 · cited 1×
“A clinical pilot study found mifepristone alleviated both the cognitive deficits and the depressive symptoms in bipolar depression [35].”
Background
Cited by
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“A two-week Phase 4 RCT examining the effects of mifepristone on cognition in AUD was recently conducted, but recruitment challenges rendered the results inconclusive [181, 182].”
BackgroundOff-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Fischler, P. V., Soyka, M., Seifritz, E., & Mutschler, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927703 · Cited by 34
The prefrontal cortex as a critical gate of negative affect and motivation in alcohol use disorder
Pahng, A. R., McGinn, M. A., Paulsen, R. I., & Edwards, S. (2017) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.11.004 · Cited by 24
Khom, S., Rodriguez, L., Gandhi, P., Kirson, D., Bajo, M., Oleata, C. S., Vendruscolo, L. F., Mason, B. J., & Roberto, M. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105610 · Cited by 23
“Alcohol dependence and withdrawal increase sensitivity of central amygdalar GABAergic synapses to the glucocorticoid receptor antagonist mifepristone in male rats Sophia Khom a,b, Larry Rodriguez a, Pauravi Gandhi a, Dean Kirson a,c, Michal Bajo a, Christopher S. Oleata a, Leandro F. Vendruscolo d, Barbara J. Mason a,…”
Influential
Metadata
- Authors
- Donoghue, K., Rose, A., Coulton, S., Milward, J., Reed, K., Drummond, C., & Little, H.
- Venue
- BMC Psychiatry
- Published
- 2016-02-24
- Volume
- 16
- Issue
- 1
- Pages
- 40-40
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W2283616911
- Cited by
- 23
- References
- 17
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double-blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol. https://app.cochat.ai/papers/10.1186/s12888-016-0757-1
- The paper
- Donoghue, K., Rose, A., Coulton, S., Milward, J., Reed, K., Drummond, C., & Little, H. (2016). Double-blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol. BMC Psychiatry. https://doi.org/10.1186/s12888-016-0757-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.